SCHEMBL5731487

SCHEMBL5731487

CCc1nc(C2=CC=C2)n2nc(-c3csc(-c4ccccc4)n3)[nH]c(=O)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
ALDH1A1 P00352 5/20 0.40
HPGD P15428 3/20 0.40
PDE5A O76074 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CDK5 Q00535 3/20 0.38
CDK5R1 Q15078 3/20 0.38
SREBF2 Q12772 1/20 0.37
APOBEC3G Q9HC16 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
LMNA P02545 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.34
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5884367 0.86 PDE5A (0.45) MAPTALDH1A1PDE5AL3MBTL1KDM4E
SCHEMBL5730697 0.79 PDE5A (0.47) MAPTALDH1A1HPGDPDE5AMEN1
SCHEMBL5731484 0.79 PDE5A (0.45) MAPTALDH1A1HPGDPDE5AMEN1
SCHEMBL5729050 0.79 ALDH1A1 (0.38) ALDH1A1HPGDPDE5ANPSR1SMN1; SMN2
SCHEMBL5730417 0.79 PDE10A (0.39) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL5884437 0.78 TNKS (0.37) PDE5ASMN1; SMN2RAB9A
SCHEMBL5884374 0.77 NPC1 (0.37) MAPTALDH1A1HPGDPDE5AMEN1
SCHEMBL5883954 0.77 MEN1 (0.38) PDE5AMEN1KMT2AGAA
SCHEMBL5884299 0.77 PIN1 (0.37) ALDH1A1PDE5AAPOBEC3GGAA
SCHEMBL5731169 0.77 ADORA2A (0.37) PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060293326-A1 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases BAYER HEALTHCARE AG (DE) 2006-12-28 US disclosed
EP-1399439-B1 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES BAYER HEALTHCARE AG (DE) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293326-A1 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases REL, AHR, SULT2A1 MAPT 4648/4885ALDH1A1 574/4885HPGD 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.